Covid-19 Disrupts Supply Chains of Medicines Revealing Yet Another Threat to Our National Security
This is
the fifth in a series of blog posts about judicial systems’ response to the
coronavirus (SARS-CoV-2 is its technical name; Covid-19 is the disease it
causes) outbreak and the justice systems’ active participation in a
whole-of-society-approach (WOSA) to national security and safety threats such
as Covid-19.
The severity
of the Covid-19 outbreak is revealing yet another national security threat to
those of which we today are well aware: the disruption of the supply chains of
lifesaving drugs produced by Chinese companies. China is the primary source of crucial medical drugs.
If this supply is in jeopardy, these drugs would stop reaching Americans.
In a
February 24 letter to the U.S. Food and Drug Administration (FDA), Senator Josh
Hawley of Missouri warned:
The novel coronavirus in China highlights severe, longstanding,
and unresolved vulnerabilities in our capacity to produce lifesaving
pharmaceutical drugs and medical devices… This is unacceptable… [The] recent
outbreak of novel coronavirus has threatened the domestic supply of some 150 prescription
drugs, including antibiotics, generics, and branded drugs. Some of these drugs
do not have alternatives on the market. The degree to which some of our own
manufacturers rely on China to produce lifesaving and life-sustaining
medications is inexcusable. It is becoming clear to me that both oversight
hearings and additional legislation are necessary to determine the extent of
our reliance on Chinese production and protect our medical product supply
chain.
As reported
yesterday by Thomas Sullivan, Editor of Policy and Medicine, similar
congressional letters echoing Senator Hawley’s warning have been sent to the
FDA by Senators Marco Rubio, Chris Murphy, Robert Menendez, and Representative
Bill Pascrell. On February 27, the FDA stated that it is aware of a drug
shortage related to an active pharmaceutical ingredients (APIs) manufacturer
affected by the spreading virus. However, the FDA stated that it could not disclose
which drug is in shortage because of confidentiality regulations. Generally speaking, noted Sullivan, under the
Food and Drug Administration Safety and Innovation Act, once a drug shortage
has been identified, it must go on a drug shortage list. However, the
legislation allows the FDA to use its discretion in not making certain
information public if the agency finds that disclosing the shortage may
adversely affect public health.
Gerald F.
Seib, writing in yesterday’s Washington Post “Capital Journal,” says that
Covid-19 is altering our views and definitions of a national security threat. He suggests that American companies need to
diversify supply chains away from China. “For years, national security
professionals have been telling one another that, in the post-Cold War world, with a globally connected
economy, nontraditional threats such as cyberattacks, biological warfare, and
global epidemics should be getting more attention,” he writes.
Copyright
CourtMetrics 2020. All rights reserved.